MedPage Today -- One of the more controversial aspects of the FDA’s 2002 approval of bone morphogenetic protein-2 or BMP-2, is the relationship between financial ties to Medtronic, the maker of BMP-2, and the procedural success rate of surgeons. That fact was noted in FDA documents labeled “confidential” that were obtained by MedPage Today and the Milwaukee Journal Sentinel under a Freedom of Information Act request.
